Krystal Biotech stock weighs Q2 growth against USD 441 target
Krystal Biotech's stock closed at USD 322.28, with Q2 revenue of USD 119.22 million, exceeding EPS consensus but falling short of revenue estimates. Analysts have set an average 12-month price target of USD 365.40, with Goldman Sachs initiating a USD 441.00 target. The company's market capitalization stands at USD 9.5 billion, and its stock remains below its yearly high.
Behavioral Patterns of KRYS and Institutional Flows
This article provides an analysis of Krystal Biotech Inc. (NASDAQ: KRYS) stock, highlighting weak near-term sentiment despite long-term strength. It includes AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, along with a multi-timeframe signal analysis for support and resistance levels.
Preferred dividends of Krystal Biotech, Inc. – HAN:4KB
This article states that Krystal Biotech, Inc. (HAN:4KB) has preferred dividends. It is listed on the Hannover Stock Exchange. The provided content is very brief and mostly consists of navigational elements and copyright information.
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an annualized return of 44.36%. An initial investment of $1000 in KRYS stock five years ago would now be worth $6,005.90. This demonstrates the power of compounded returns in investment growth.
Krystal Biotech stock initiated at buy by Goldman Sachs
Goldman Sachs has initiated coverage on Krystal Biotech Inc. (NASDAQ:KRYS) with a "buy" rating and a price target of $441.00, citing the company's profitable gene therapy platform for rare diseases. Krystal Biotech's lead commercial drug, Vyjuvek, has achieved significant market penetration, and the company boasts a robust clinical pipeline. Despite a recent revenue miss in Q2, the stock is considered undervalued by InvestingPro analysis.
Krystal Biotech Price Target Announced at $441.00/Share by Goldman Sachs
Goldman Sachs has set a price target of $441.00 per share for Krystal Biotech (KRYS). This new target indicates a potential upside for the company's stock, reflecting Goldman Sachs' analyst outlook.
Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441
Goldman Sachs has reiterated its Buy rating on Krystal Biotech (KRYS.US) and increased its price target from $437 to $441. This revised target suggests a potential upside of 32.89% from the company's previous closing price of $331.09. The update reflects Goldman Sachs' continued confidence in Krystal Biotech's future performance.
Krystal Biotech stock initiated at buy by Goldman Sachs
Goldman Sachs has initiated coverage of Krystal Biotech (NASDAQ: KRYS) with a buy rating and a price target of $441, indicating significant upside potential. The biotechnology company, which is profitable and commercial-stage, specializes in gene therapy for rare diseases and boasts high gross profit margins. Its lead product, Vyjuvek, for dystrophic epidermolysis bullosa, has high market penetration and a pipeline of other clinical candidates.
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400
BofA Securities has reiterated its Buy rating on Krystal Biotech (KRYS.US) and increased its price target from $200 to $400. This updated target suggests a potential upside of 74.34% from the stock's last closing price of $229.44.
KRYSTAL BIOTECH, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $400 FROM $392
BofA Global Research has raised its price objective for Krystal Biotech, Inc. (KRYS.O) to $400 from $392. This adjustment reflects an updated outlook from the research firm regarding the biotechnology company's valuation. The article states that this content solely reflects the author's opinion and should not be used as investment advice.
BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating
BofA has increased its price target for Krystal Biotech (KRYS) to $400 from $392, while maintaining a Buy rating on the stock. The adjustment reflects BofA's continued positive outlook on the biopharmaceutical company. Krystal Biotech specializes in genetic medicines and has a commercial product, VYJUVEK, approved for treating dystrophic epidermolysis bullosa.
Rossi Dino A Granted 1,658 Derivative Securities of Krystal Biotech, Inc. on September 14, 2026
Rossi Dino A was granted 1,658 derivative securities of Krystal Biotech, Inc. on September 14, 2026, through two separate transactions. Each transaction was recorded at $0 per share, indicating these were awards rather than market purchases or sales, as designated by SEC transaction code A. Krystal Biotech, Inc. is traded under the ticker symbol KRYS.
Krystal Biotech (KRYS) board member receives new options and RSUs
Krystal Biotech, Inc. (KRYS) director Christopher Mason was granted 1,187 stock options and 471 restricted stock units (RSUs) on September 14, 2026. The stock options have an exercise price of $340.03 and expire in 2036. Both the options and RSUs are set to vest fully on September 14, 2027, contingent upon his continued service on the Board of Directors.
Director at Krystal Biotech (KRYS) gets new stock options and RSUs
Krystal Biotech (KRYS) director Catherine Mazzacco was granted 1,187 stock options and 471 restricted stock units (RSUs) on September 14, 2026, as part of her board compensation. The stock options have an exercise price of $340.03 per share and expire on September 13, 2036. Both the stock options and RSUs are set to vest in full on September 14, 2027, provided Mazzacco continues her service on the company's Board of Directors.
Krystal Biotech (NASDAQ: KRYS) Grants Director Janney Daniel 1,658 Derivative Securities at Zero Cost
Krystal Biotech (NASDAQ: KRYS) awarded director Janney Daniel 1,658 derivative securities at zero cost on September 14, 2026. This transaction, classified under SEC code A, signifies an award rather than a purchase or sale. Janney Daniel is a recognized director of the company, and the securities were granted at a price of $0 per share.
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing
An insider at Krystal Biotech sold shares valued at $8,983,084, as reported in a recent SEC filing. This transaction follows other recent insider sales and significant company news, including Q2 earnings results and analyst ratings. Krystal Biotech is a commercial-stage biotechnology company focused on genetic medicines.
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS)
Krystal Biotech President Krishnan Suma sold 25,000 shares of the company's stock across 13 transactions on September 4, 2026, with prices ranging from $354.54 to $366.56 per share. Following these sales, Suma's ownership in Krystal Biotech (NASDAQ: KRYS) stands at 1,302,145 shares. The details of these transactions were filed with the SEC, updating investors on his post-transaction holdings.
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing
An insider at Krystal Biotech (KRYS) recently sold shares valued at $8,982,986, as reported in a recent SEC filing. This transaction follows other insider share sales reported in August, with amounts ranging from $8.2 million to $8.9 million. The company, a commercial-stage biotechnology firm, specializes in genetic medicines and has products like VYJUVEK approved in the US and Europe.
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan
Suma Krishnan, President of R&D and a ten percent owner at Krystal Biotech (KRYS), sold 25,000 shares of common stock on September 4, 2026, through a Rule 10b5-1 trading plan that has since terminated. The sales were executed at prices ranging from $353.98 to $366.91 per share. Following these transactions, Krishnan maintains significant indirect holdings through several family trusts, totaling over 190,000 shares.
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock
Suma Krishnan, President of Research & Development at Krystal Biotech Inc., sold 27,000 shares of company stock for approximately $8.98 million on September 4, 2026, under a Rule 10b5-1 trading plan. These sales occurred as KRYS stock trades near its 52-week high after a 139% return over the past year. Following the transactions, Krishnan still holds significant direct and indirect shares in Krystal Biotech.
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference
Krystal Biotech, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will hold a fireside chat and investor meetings. The company, a commercial-stage biotechnology firm, focuses on genetic medicines and has its first product, VYJUVEK®, approved in major markets.
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?
Krystal Biotech (KRYS) reported strong Q2 2026 net income and earnings per share, primarily driven by its gene therapy, Vyjuvek. While these results highlight increased profitability, the article emphasizes that the core investment narrative still revolves around the successful global rollout of Vyjuvek and managing risks related to revenue volatility, margin pressure, and unpredictable treatment patterns. Investors are encouraged to consider these factors alongside the positive earnings.
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS
The State of Wyoming recently acquired a new stake in Krystal Biotech, purchasing 4,767 shares valued at approximately $1.77 million during the second quarter. Krystal Biotech reported strong Q2 earnings, beating EPS estimates, and institutional investors now collectively own 86.29% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for KRYS, with a consensus price target of $365.40, following several recent upgrades.
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?
Krystal Biotech reported strong Q2 2026 net income and EPS, largely driven by its drug Vyjuvek. While these results bolster the company's investment narrative, the core risk remains the execution of Vyjuvek's global rollout and potential revenue volatility due to patient treatment patterns, pricing, or reimbursement. The recent UK marketing authorization for Vyjuvek underscores the importance of successful international expansion, alongside the less visible risk of unpredictable treatment pauses affecting return stability.
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada
Royal Bank of Canada upgraded Krystal Biotech (NASDAQ:KRYS) to a "moderate buy" rating, aligning with a generally bullish analyst consensus. The company, which has a market capitalization of $9.83 billion, recently reported quarterly earnings that beat expectations but revenue that slightly missed. Insider selling of shares has occurred, while institutional investors hold a significant portion of the stock.
Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares
Krystal Biotech (KRYS) Director Dino Rossi sold 25,000 shares of the company on August 14, 2026, for approximately $8.23 million, reducing his direct ownership to 50,000 shares. This sale continues a trend of insider selling over the past year, with no insider buys reported, yet the stock is considered "Fairly Valued" by GuruFocus's proprietary model. Despite insider selling, institutional interest remains strong, with a majority of gurus increasing their positions, suggesting confidence in the company's long-term prospects.
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock
Krystal Biotech (KRYS.US) Director, Daniel Meyer, sold 84,200 shares of common stock on August 13, 2026, for a total of $8.23 million. The shares were sold at an average price of $97.75. Following this transaction, Meyer directly owns 10,000 shares of the company.
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock
Krystal Biotech Director Dino Rossi sold 25,000 shares of the company's stock on Friday, August 14th, at an average price of $329.12 per share, totaling $8.23 million. Following this transaction, Rossi's stake in the company decreased by 33.33% to 50,000 shares. Despite the insider selling, Krystal Biotech shares rose 1.2% on Friday, and analysts maintain a "Moderate Buy" rating with an average target price of $365.40.
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026)
This article reports on a Form 144 SEC filing by Krystal Biotech, Inc. (KRYS) on August 14, 2026. The filing indicates a proposed sale of 25,000 shares of common stock with an aggregate market value of $8,306,750, acquired from the public market on September 22, 2017. The sentiment and impact of this filing are deemed neutral by StockTitan's AI analysis.
KRYSTAL BIOTECH, INC. : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $400
RBC Capital Markets has initiated coverage on Krystal Biotech, Inc. (KRYS.O) with an Outperform rating. The firm has set a target price of $400 for the biotechnology company. This announcement was made on August 14, 2026.
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target
RBC Capital Markets has initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, citing strong positioning for future gains from its product VYJUVEK and a promising pipeline. The biotech company, which specializes in genetic medicines, recently reported Q2 2026 earnings with a net income and product revenue increase, despite missing FactSet's revenue estimates. Krystal Biotech is also developing several other product candidates for various diseases, including Cystic Fibrosis and solid tumors.
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus
Krystal Biotech (KRYS) reported strong Q2 2026 earnings with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, leading to a significant year-to-date share price return. Despite a recent short-term decline, the company is trading below analyst price targets, and its expanding pipeline in various medical fields suggests potential for future revenue growth. The valuation debate centers on an estimated fair value of $361.67, driven by pipeline expansion and favorable healthcare dynamics for genetic therapies.
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus
Krystal Biotech (KRYS) reported strong Q2 2026 results with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, contributing to significant year-to-date and 1-year share price returns. Despite a recent short-term dip, the company trades below analyst targets and intrinsic value estimates. Its pipeline expansion into lung disease, ophthalmology, oncology, and aesthetics, alongside favorable healthcare trends, positions it for future growth and diversified earnings.
Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS
Bank of America Corp DE significantly increased its stake in Krystal Biotech (NASDAQ:KRYS) by 36.6% in the first quarter, now owning 260,647 shares valued at $67.3 million. Other institutional investors also raised their positions, leading to institutional ownership of 86.29%. The company reported strong quarterly earnings of $1.79 per share, beating estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $361.56.
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
Krystal Biotech (KRYS) reported strong Q2 2026 results, with net product revenue up 24% to $119.2 million, driven by VYJUVEK sales and expansion into community settings. The company achieved 730+ U.S. reimbursement approvals and is advancing a robust clinical pipeline, including registrational studies for ocular indications and oncology programs. Krystal Biotech is transitioning to a multi-product genetic medicines company, with several key data readouts and new registrational trial initiations expected in late 2026 and 2027.
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An initial investment of $1000 in KRYS five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company currently holds a market capitalization of $9.69 billion.
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An investment of $1000 in KRYS stock five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company currently has a market capitalization of $9.69 billion.
Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS
Renaissance Technologies LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 190.9% in the first quarter, now holding 9,600 shares valued at approximately $2.48 million. Other institutional investors have also adjusted their positions, with institutions collectively owning 86.29% of the stock. Analysts maintain a positive outlook with a "Moderate Buy" consensus rating and an average price target suggesting further upside from the current trading price.
California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS
The California State Teachers Retirement System increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.2% in the first quarter, now holding 26,186 shares valued at $6.76 million. Krystal Biotech reported strong Q1 earnings per share of $1.79, beating analyst estimates, although revenue slightly missed expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $361.56 despite recent insider stock sales.
Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact
Krystal Biotech (KRYS) reported strong Q2 2026 results, exceeding analyst expectations with robust Vyjuvek sales and expanding market reach. Despite a recent short-term share price dip, longer-term performance remains strong. The article discusses two valuation perspectives: one suggesting the stock is 10.2% undervalued based on a narrative of pipeline expansion and favorable healthcare dynamics, and another from a DCF model indicating it is significantly undervalued at $1,054.32 compared to its current price of $324.77.
The Manufacturers Life Insurance Company Cuts Stake in Krystal Biotech, Inc. $KRYS
The Manufacturers Life Insurance Company reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.2% in the first quarter, selling 4,560 shares and retaining 36,069 shares valued at approximately $9.3 million. Despite beating EPS estimates, Krystal Biotech's revenue fell short of analyst forecasts, though demand for VYJUVEK remains strong. Analysts maintain a "Moderate Buy" rating with an average price target of $360.67, recognizing risks like higher expenses and international reimbursement negotiations.
KRYSTAL BIOTECH INC : BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $392 FROM $396
BofA Global Research has lowered its price objective for Krystal Biotech Inc. (KRYS.O) from $396 to $392. This adjustment reflects a revised outlook from the research firm regarding the biotechnology company. The article provides this key financial update from Reuters.
Krystal Biotech Inc Unsponsored BDR Revenue Breakdown – BMFBOVESPA:K1YS34
This article provides a revenue breakdown for Krystal Biotech Inc Unsponsored BDR (K1YS34). It highlights that the company generated 2.14 billion BRL last year, primarily from its Genetic Medicines segment and the United States market. The information is presented within the context of TradingView's financial data offerings.
Krystal Biotech (KRYS) Stock Price Drops As Premium Expectations Reset
Krystal Biotech's stock price dropped 8% after its Q1 2026 earnings report, despite solid revenue and profit growth. This decline is attributed to a reset in investor expectations rather than poor financial performance. While the company's gene therapy, VYJUVEK, shows strong gross margins and continued demand, concerns about international reimbursement friction and increased general & administrative costs contributed to the market's reaction.
Krystal Biotech Shares Fall After Q2 Product Revenue Miss
Krystal Biotech (KRYS) shares declined after the company reported second-quarter product revenue of $119.2 million, which missed FactSet estimates of $120.9 million. Despite the revenue miss, the company's Q2 EPS of $1.79 exceeded the FactSet estimate of $1.62. The biotechnology company focuses on genetic medicines and recently had its commercial product, VYJUVEK, approved in the United States and Europe for treating dystrophic epidermolysis bullosa.
Krystal Biotech Releases Q2 2026 Financial Results
Krystal Biotech (KRYS) announced strong Q2 2026 financial results, with diluted earnings per share of $1.79, beating the consensus estimate of $1.69. The company reported net income of $54.8 million and generated $119.2 million in revenue, a 24.0% increase year-over-year. This performance reflects increasing adoption of its genetic medicine platform and has led to an optimistic outlook from Wall Street analysts.
Krystal Biotech (KRYS) Q2 2026 Earnings
Krystal Biotech (KRYS) reported its Q2 2026 earnings, missing both EPS and revenue estimates. Despite the miss, the company highlighted 24% revenue growth for its product VYJUVEK and anticipates several pipeline readouts over the next 12 to 18 months, signaling a potential shift towards becoming a multi-product company.
Krystal Biotech stock falls 7% on revenue miss despite earnings beat
Krystal Biotech (NASDAQ:KRYS) reported Q2 results with adjusted EPS of $1.79, beating analyst estimates, but product revenue of $119.2 million missed the forecast of $122.3 million, causing its stock to fall 7.65% in pre-market trading. Despite the revenue miss, the company's VYJUVEK product showed strong performance with a 95% gross margin, and the company maintains a strong balance sheet with $1.1 billion in cash and investments, while also providing full-year 2026 guidance for adjusted expenses.
Krystal Biotech Q2 Earnings Beat Expectations
Krystal Biotech reported Q2 GAAP EPS of $1.79, exceeding expectations by $0.16, and achieved $119.22 million in revenue, a 24.1% year-over-year increase, despite a slight miss on revenue estimates. The company's product VYJUVEK has generated $965.9 million in global revenue since launch, demonstrating strong market acceptance. Krystal Biotech provided FY 2026 guidance for non-GAAP R&D and SG&A expenses between $175 million and $195 million, reflecting confidence in future investments.
Krystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summary
Krystal Biotech reported strong second-quarter 2026 results, with revenue reaching $119.22 million and diluted EPS at $1.79, largely driven by increased VYJUVEK sales and successful market expansions. The company achieved significant year-over-year growth in revenue, net income, and EPS, supported by high gross margins and advancing R&D pipeline. VYJUVEK's expansion into new markets like the EU and Japan, along with new approvals, continues to fuel its performance.
